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Abstract
Background: Pragmatic randomised controlled trials are often used in primary care to evaluate the effect of a
treatment strategy. In these trials it is difficult to achieve both high internal validity and high generalisability. This
article will discuss several methodological challenges in designing and conducting a pragmatic primary care based
randomised controlled trial, based on our experiences in the DIAMOND-study and will discuss the rationale
behind the choices we made. From the successes as well as the problems we experienced the quality of future
pragmatic trials may benefit.
Discussion: The first challenge concerned choosing the clinically most relevant interventions to compare and
enable blinded comparison, since two interventions had very different appearances. By adding treatment steps to
one treatment arm and adding placebo to both treatment arms both internal and external validity were optimized.
Nevertheless, although blinding is essential for a high internal validity, it should be warily considered in a pragmatic
trial because it decreases external validity. Choosing and recruiting a representative selection of participants was
the second challenge. We succeeded in retrieving a representative relatively large patient sample by carefully
choosing (few) inclusion and exclusion criteria, by random selection, by paying much attention to participant
recruitment and taking the participant's reasons to participate into account. Good and regular contact with the
GPs and patients was to our opinion essential. The third challenge was to choose the primary outcome, which
needed to reflect effectiveness of the treatment in every day practice. We also designed our protocol to follow
every day practice as much as possible, although standardized treatment is usually preferred in trials. The aim of
this was our fourth challenge: to limit the number of protocol deviations and increase external validity.
Summary: It is challenging to design and conduct a pragmatic trial. Thanks to thorough preparation, we were
able to collect highly valid data. To our opinion, a critical deliberation of where on the pragmatic – explanatory
spectrum you want your trial to be on forehand, in combination with consulting publications especially on patient
recruitment procedures, has been helpful in conducting a successful trial.
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Background
Pragmatic trials are designed to investigate how effective a
treatment strategy is in everyday practice [1]. The hypoth-
esis and study design in pragmatic trials are developed
specifically to answer questions of decision makers and
should compare new with existing interventions in the
indicated population using relevant health outcomes
[2,3]. Researchers face a number of methodological chal-
lenges and need to make several choices in the design and
conduct of pragmatic trials. This is especially true for pri-
mary care based trials where the broad spectrum of disease
presentation and early clinical stage challenges the selec-
tion of an adequate study population. Though these chal-
lenges greatly influence the external and internal validity
as well as the eventual significance of the study results,
most publications do not elaborate on the choices made.
This paper discusses several challenges in designing and
conducting pragmatic primary care based trials we experi-
enced in a large scale multicentre randomised trial on dys-
pepsia. This might be helpful for other researchers
especially in the planning stage of new trials. Our objec-
tive is to contribute to quality improvement of pragmatic
primary care based trials.
This paper will discuss three challenges in designing a
study: choosing the right intervention and blinding treat-
ment allocation, choosing an appropriate study popula-
tion, and choosing the essential outcome measures.
Subsequently the challenges in conducting a study will be
discussed focusing on recruitment of participating general
practitioners (GPs) and patients, and on dealing with pro-
tocol deviations. Each section will start with a brief intro-
duction of pitfalls in general, followed by the rationale
behind the choices made within the DIAMOND-study
and a speculation of the consequences of our choices. The
paper will end with conclusions describing the conse-
quences of our choices for the expected usefulness and rel-
evance of the DIAMOND results.
The DIAMOND trial
The Dutch study of InitiAl Management Of Newly diagnosed
Dyspepsia (DIAMOND) investigates the effectiveness of two
treatment strategies for dyspepsia: the step-up treatment strat-
egy and the step-down treatment. The step-up treatment starts
with antacids and, if the symptoms persist or recur, builds up to
stronger medication, while the step-down treatment starts with
the strongest drug (proton pump inhibitor (PPI)) and reduces
stepwise to H2-Receptor Antagonists (H2RA) and antacids as
long as the symptoms persist or recur. In Table 1, 2, 3, 4 and
Figure 1, 2 the design and research questions of the DIA-
MOND-study are described. The protocol of DIAMOND is
registered on (identifier: NCT00247715) [4]. It is a prag-
matic, large multicentre randomised controlled trial in primary
care running from 2003 till 2007, in which 664 patients with
dyspepsia were included and more than 300 GPs participated.
The study is conducted with the joint expertise of three aca-
demic research centres from both primary and secondary care.
While within DIAMOND besides effectiveness also cost-effec-
tiveness will be analysed, this paper will focus on the evaluation
of clinical end-points. Economic evaluation trials are facing
specific methodological challenges, which are described for
instance by Ramsey et al. and Tunis et al. [3,5].
Discussion
Challenges in designing a study
Choosing the right intervention and blinding treatment allocation
Pragmatic trials evaluate the beneficial effect of a treat-
ment strategy for clinical practice when applied by any cli-
nician to any patient with the disorder studied. The
intervention must be relevant and feasible to be general-
ised to clinical practice and it must be compared to the
best available usual care (reference care). Randomisation
and blinding caregivers, participants, and investigators for
treatment allocation are used in trial settings to increase
the internal validity and aims to ensure that an effect is
solely caused by the intervention[6]. Inadequate blinding
in trials proved to result in 30% lower odds ratios than
adequate blinding[7]. However, in every day practice
treatment is not blinded, and may be influenced by prej-
udices of GPs or patients. While blinding is important to
increase internal validity, it may limit the generalisability
of results. Furthermore, blinding treatment allocation is
often difficult to achieve in pragmatic trials, because of
differences in the appearance of treatment (for instance
operation versus medication) or differences in the consul-
tation scheme.
One possible solution is cluster randomisation[6], where
one group of caregivers exclusively prescribes the experi-
mental treatment and another exclusively the reference
treatment. When all physicians within one centre are allo-
cated to the same treatment arm, contamination will be
Table 1: The primary and secondary aims of DIAMOND
Primary aim of DIAMOND:
• To investigate which treatment strategy, "step-up" or "step-down" treatment, was the most (cost-)effective initial management strategy for 
patients with a new episode of dyspepsia in primary care.
Secondary aims of DIAMOND:
• To investigate which factors influence the severity of the GI complaints.
• To investigate which factors determine compliance with dyspepsia medication prescriptions and compliance with advised lifestyle changes.
• To investigate which factors influence treatment success.BMC Medical Research Methodology 2007, 7:16 http://www.biomedcentral.com/1471-2288/7/16
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reduced and all patients within one centre get the same
treatment. Nevertheless, prejudices of caregivers, patients
or researchers might still cause observation bias, for
instance if the treatment is terminated preliminarily when
physicians or patients do not expect the treatment to
work. Although this reflects every day practice and might
not be a problem in pragmatic trials (as long as patients
are still included in analyses), observation bias decreases
internal validity. Furthermore, because differences
between caregivers can bias the results, one should then
adjust for these differences with multi-level analysis.
The rationale behind our choices
The DIAMOND project was designed to compare a step-up
treatment strategy (Figure 1) (which is advocated in recent
Dutch guidelines) with PPI-treatment (which is practised by
many GPs). The appearances of both strategies differ too much
to be suitable for blinding. Therefore, we decided to compare the
step-up treatment strategy with a step-down treatment strategy,
in which the PPI-treatment is followed by two treatment steps
(Figure 1). Both treatment strategies were now made compara-
ble in drug distribution and appearances by using placebos (Fig-
ure 2). This had several advantages; first, this design enables to
investigate whether patients experience symptom relief on other
(non-PPI) acid-suppressants when initial PPI-treatment fails.
Second, PPIs can have a known rebound effect. In the step-
down group it is possible to investigate whether patients, who
initially responded well on PPIs but got a relapse, respond
equally well on other (cheaper) acid-suppressants. Third, when
patients needed all three medication steps, both groups received
the same medication, only in a different order, so the influence
of the order of medication on for example patient satisfaction
can be investigated.
Our design also had some disadvantages. Our organisation of
"step-down" treatment does not reflect usual care, which might
affect generalisability. Some argued it is unethical to 'step-
down' when the strongest drug is not effective. However, in our
opinion patients can safely try the other two kinds of medica-
tion, before further investigation is established. Furthermore, in
both groups patients had to use a placebo along with normal
treatment. This can be a burden, since it means taking extra
pills in step 1 and step 3, and it differs from everyday practice
too.
Although heavily aimed for, we were not able to find completely
identical placebos. However, patients would not be able to tell
their treatment allocation and to ensure that GPs would not
recognize the pills, non-transparent medication jars packed in
sealed paper bags were used. Clustered randomisation as dis-
cussed above could have induced more bias as the treatment
allocation would have been recognized easily by GPs after com-
pleting the first patient in their cluster.
We chose to disclose treatment allocation at 6 months, just after
measuring primary outcome. We reached high internal validity
Table 3: DIAMOND inclusion and treatment protocol
1. When a patient visits the GP, the inclusion and exclusion criteria are checked.
2. When the patient meets the criteria, the GP informs the patient about DIAMOND. When the patient wants to participate, he or she provides an 
informed consent.
3. The GP hands out the patient the medication for step 1. The medication is packed in boxes and is provided to the GP at the start of the study. 
Each box contains all the medication steps for one patient. The patient numbers on the boxes are linked to the numbers on the randomisation list 
in a sealed envelope kept at the researchers' office.
4. A blood sample is taken.
5. The patient receives the first questionnaire from the GP to fill out at home. Other questionnaires are sent to patients (Table 4).
6. The patient is treated according to the treatment protocol (see Figure 1 and 2). If the symptoms continue or relapse within 8 weeks after starting 
the medication step, the patient starts with the next treatment step. It is possible to shorten the treatment steps into less than 4 weeks, for 
instance when the patient suffers from side effects. The patient and GP are advised to schedule a follow-up visit at 4 weeks, which should be 
cancelled when the complaints are resolved.
7. When symptoms continue or relapse after medication step 3, the GP can treat the patient according to their own judgement.
8. The GP and the patient are informed six months after inclusion about the treatment allocation and the test results from the blood sample 
(whether the patient was infected with Helicobacter pylori).
Table 2: Inclusion and exclusion criteria of DIAMOND
1. Patients are included when they visit their GP for complaints of which the GP thinks that they originate from the upper GI tract and for which 
acid-suppressive medication can be effective.
2. Patients are included when they are 18 years or older.
3. Patients are excluded when they have used prescribed acid-suppressive medication in the last 3 months before inclusion.
4. Patients are excluded when they have had a gastroscopy in the year prior to inclusion.
5. Patients are excluded when they have alarming symptoms.
6. Patients are excluded when there are contraindications for prescribing acid-suppressive medication, such as pregnancy, liver or kidney 
malfunction.
7. Patients are excluded when they are not able to fill out (Dutch) questionnaires, for example because of language problems.BMC Medical Research Methodology 2007, 7:16 http://www.biomedcentral.com/1471-2288/7/16
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at the cost of decreasing external validity. Primary outcome
(adequate symptom relief according to the patient) was meas-
ured at 6 months, which could be 3–4 months after prolonged
prescription of any medication chosen by the GPs after complet-
ing the trial. In usual care the GP would repeat prescription of
the most effective on recurrence of the symptoms. However,
because of the "late" disclosure of treatment allocation in DIA-
MOND, our GPs may have assumed that symptom relief may
have occurred during the use of PPI and prescribed this after the
trial medication was finished, while maybe the patient
responded on the antacid. Consequently, blinding might have
caused convergence of treatment after trial medication in both
strategies, which decreases differences in measured effective-
ness.
Infection with Helicobacter pylori can influence the effectiveness
of treatment as well as relapse rates of symptoms. Therefore blood
samples for serology were taken at baseline. The H pylori test
results were also disclosed at 6 months to avoid the treatment or
costs to be influenced by H pylori management before measuring
primary outcome. Incidentally GPs requested to disclose H pylori
test results earlier, in which case, the (theoretical) costs of H
pylori testing were included for the cost evaluation of treatment.
The medical ethics committee agreed with postponed disclosure
since H pylori infection takes place early childhood and has no
imminent association with the onset of symptoms. Early H pylori
testing in this trial may have caused GPs to be more aware of H.
pylori infection and may have urged them to inform about the
test results more often than in normal practice. However, the
alternatives, drawing blood samples only when a test is requested
DIAMOND: Treatment strategies Figure 1
DIAMOND: Treatment strategies. * If the symptoms persisted the patient continued with the next treatment step. If the symp-
toms initially were relieved but relapsed within 4 weeks after stopping the treatment step, the patient also started the next 
treatment step. Otherwise (in case of a relapse after 4 weeks), the GP could treat the patient to their own judgement. Antac-
ids (Algedrate-Magesiumoxide); H2RA: H2-receptor antagonist (Raniditine); PPI: Proton Pump Inhibitor (Pantozole).
Randomize
Step-up
Step-down PPI H2RA Antacids
PPI H2RA Antacids
Step 1 Step 2 Step 3
No DIAMOND 
medication
Symptoms 
persist or 
relapse < 4 
weeks?*
Symptoms 
persist or 
relapse < 4 
weeks?*
Yes
No No
Yes
Yes Yes
No No
Table 4: Measurements
Primary health outcome: Adequate symptom relief at 6 months according patients
Secondary health outcomes:
Severity of the GI complaints (at 2 weeks and after each treatment step)
Quality of life at 6 months (at 2 weeks and after each treatment step)
Additional research questions investigated:
- The cost-effectiveness of both treatment strategies.
- The association between genetic determinants and dyspepsia and treatment success.
- Compliance with prescribed medication advices and life-style advices and which factors influence compliance.
- The association between psychosocial determinants and dyspepsia and treatment success.
Self-administered questionnaires used:
- General questionnaire to measure effect of the treatment, costs, work absenteeism, demographical determinants, co-medication used and life-
style.
- Gastrointestinal Symptoms Questionnaire; EuroQol 5D; SF 36; Compliance Questionnaire; SCL 90; Health Hardiness; Utrechts Coping List; Major 
Life EventsBMC Medical Research Methodology 2007, 7:16 http://www.biomedcentral.com/1471-2288/7/16
Page 5 of 11
(page number not for citation purposes)
by the GP or after follow-up is completed, would have caused
more drop-outs. The choice to communicate H. pylori test results
at 6 months and take theoretical costs into account when
requested sooner is a clear example of a way to control the treat-
ment, while it probably decreases the external validity.
Our choices may all influence treatment effects. We believe that
blinding the treatment allocation and the use of placebo led to
more comparable treatment strategies, which probably led to a
smaller difference between the true effects of both treatment
strategies than in every day practice would exist.
Choosing an appropriate study population
Regarding internal validity, according to Kleinbaum et al.
selection bias is a distortion in the estimate of effect result-
ing from the manner in which subjects are selected from
the target population [8]. Within DIAMOND all patients
were randomly allocated to either the step-up or step-
down treatment strategy, which makes selection bias
unlikely.
Regarding external validity, it is very important that the
investigated population should represent the target popu-
lation, but how can optimal representation be achieved?
First, the target population needs to be clearly defined by
using inclusion and exclusion criteria. Second, the
method of patient selection greatly influences representa-
tion (see "Patient recruitment"). The best way is to select
patients randomly, but this is very challenging because it
is difficult to avoid self-selection. Responding to an adver-
tisement is a clear example of self-selection. Also GPs may
be self-selected if they responded to an invitation letter to
participate. This can be a problem when the participation
of the GPs is associated with certain patient characteristics
(education level, co-morbidity).
A representative patient sample must reflect all patients in
the target population, including patients from minority
groups, especially when treatment effects are supposed to
be influenced by population characteristics. Translated
questionnaires should enable immigrants to participate.
Consideration should always be given to motivate
patients expected to have low participation rates, for
instance by tailoring patient information to gender or age.
There are several practical or judgemental reasons (lack of
time, symptoms, preference, willingness) for a patient not
to be included although eligible. Therefore, registration of
all eligible patients and monitoring reasons for non-inclu-
sion is preferred, to be able to judge inclusion selection.
However, this is time consuming and researchers still
would question the completeness of the registration.
When available, electronic medical records might be help-
ful in estimating the proportion of non-included eligible
patients. However, routine electronic medical records
might also lack data to check eligibility (e.g. duration of
symptoms) and won't always provide insights in the rea-
sons for non-inclusion.
The rationale behind our choices
We chose to focus on "adult patients with a new episode of dys-
pepsia", because the most effective treatment for these patients
was unknown. Careful consideration with all the experts in the
research board led to a limited number of inclusion and exclu-
sion criteria to define these patients. The criteria were based on
recent guidelines and were judged to be feasible and clear
DIAMOND: Blinding of the treatment strategies Figure 2
DIAMOND: Blinding of the treatment strategies. Antacids (Algedrate-Magesiumoxide); H2RA: H2-receptor antagonist (Ranidi-
tine); PPI: Proton Pump Inhibitor (Pantozole).
Step 1 Step 2 Step 3
Step-up PPI H2RA Antacids
+ Placebo PPI + Placebo 
Antacids
Step-down PPI H2RA Antacids
+ Placebo PPI + Placebo 
AntacidsBMC Medical Research Methodology 2007, 7:16 http://www.biomedcentral.com/1471-2288/7/16
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GP Recruitment Figure 3
GP Recruitment.
2725 GPs invited to participate by a letter
711 reacted by fax: 575 were not interested in participation 
40 were interested but like to be contacted later
of which 1 requested an informal talk
24 requested more written information 
of which 11 then requested an informal talk
72 requested an appointment for an informal talk 
895 contacted by phone:  474 were not interested in participation 
133 were interested but like to be contacted later
of which 1 requested an informal talk 
40 requested more written information 
of which 10 then requested an informal talk
248 requested an appointment for an informal talk
116 could not be reached (had moved or on sick-leave or were retired)
343 appointments for informal talks:
31 did not want to participate, their main reason:
- the financial incentive was too small (4)
- the patient inclusion cost too much time (18)
- other (like retirement in near future) (9)
312 GPs in 221 practices participated (mean period 526 days, range 112-882 )
150 GPs in 127 practices have recruited one or more patientsBMC Medical Research Methodology 2007, 7:16 http://www.biomedcentral.com/1471-2288/7/16
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(Table 2). Regarding the representation of minority groups, it
was not possible to make all relevant language adjustments, but
translation from Dutch into English was provided. Some partic-
ipating immigrants who spoke other languages had help from
their relatives to fill out the questionnaires.
Patients were recruited by participating GPs. We invited as
many GPs as possible within our geographic boundaries, result-
ing in 312 participating GPs distributed over the Netherlands
(Figure 3). It is possible that especially GPs with a special inter-
est in the gastrointestinal (GI) field were responding. This can
be a problem if participation of the GPs is associated with effect
modifying patient characteristics. However, it is likely that the
heterogeneous group of participating GPs (GPs from urban as
well as rural regions with solo, duo, or group practices) has
resulted in a heterogeneous patient sample, which represents
the primary care population.
To investigate initial treatment of patients with a "new" episode
of dyspeptic symptoms, patients who used prescribed acid-sup-
pressive drugs in the last 3 months were excluded. However,
since patients with mild symptoms are more likely to be without
medication for more than 3 months than patients with severe
symptoms, this might have resulted in a patient sample with
overrepresentation of patients with mildly severe dyspepsia.
Moreover, maybe the GPs only invited patients with mildly
severe dyspepsia, because they did not want to risk patients with
more severe complaints to be treated with the step-up treatment
strategy. Finally the representativeness of our sample will be
investigated by comparing several relevant patient characteris-
tics to results from other (preferably population based) studies.
Hypothetically, the difference in treatment effect between PPIs
and antacids might be smaller in patients with mild symptoms.
As a consequence the difference between the two treatment
strategies might have been smaller than in every day practice
where also patients with more severe complaints are treated.
Choosing the essential outcome measurements
The value of study results is greatly determined by the def-
inition of the primary outcome and choice of measure-
ments. When the primary outcome is an objective
measure, e.g. survival, it is easy to measure and define it.
However, the outcome of many diseases in primary care
needs more subjective evaluation, and selection and defi-
nition of the outcome may prove to be difficult. A proper
definition can be based on literature or expert opinion.
Furthermore, it needs to reflect what decision makers
want to know. The endpoint also needs to be clear, and
preferably comparable with other studies.
Concerning the measurements, the validity and reliability
should always be critically assessed. To increase response
rates questionnaires must be as short as possible. This is
challenging, especially when several additional research
questions are investigated as in our study (see Table 4).
The additional value of every question in the question-
naire needs to be critically judged and a pilot study is pre-
ferred to estimate the feasibility and burden for GPs and
patients.
The rationale behind our choices
Choosing the primary outcome measure for DIAMOND was
not easy because the presence or absence of "dyspepsia" can not
be measured objectively[9]. Furthermore, dyspepsia is charac-
terized by periods of remission followed by symptom relapse. We
used "adequate symptom relief at 6 months, according to the
patient" as primary outcome, following expert recommenda-
tions (Rome II criteria) and because this reflects the decision to
stop or continue treatment in every day practice. It is generally
accepted that symptomatic response can be used in dyspepsia
because this is what GPs have to rely on in clinical practice.
Besides, more objective measurements (e.g. endoscopy) poorly
correlate with symptom severity. To enable a comparison with
results from other studies we analysed the change in severity of
the gastrointestinal symptoms and quality of life as secondary
outcomes.
Additionally, choosing the right timing of the measurement of
the primary outcome in a study with multi-step treatment strat-
egies is difficult. Choosing a 6 month time interval is conven-
ient for policy makers and feasible in trial practice. But the
downside is that patients received trial medication for variable
periods of time. Good responders may only have had the first
treatment step, and if they remained symptom-free for 4 weeks
after finishing treatment they did not start with the second
treatment step. In case of relapse after 4 weeks or after finishing
treatment step 3 treatment was left up to the GP. As mentioned
above, primary outcome might be influenced more by the GP
Patient recruitment and number of (successful) GP partici- pants Figure 4
Patient recruitment and number of (successful) GP partici-
pants.BMC Medical Research Methodology 2007, 7:16 http://www.biomedcentral.com/1471-2288/7/16
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prescribed medication than study medication at the time of 6
months. This may have decreased differences between the treat-
ment strategies at 6 months. We also measured short term out-
comes (at 2 weeks, 4 weeks, etc.) to be able to determine the
short-term efficacy of the individual treatment strategies.
We investigated the validity of the questionnaire for the severity
of gastrointestinal complaints [10,11]. A pilot study among
non-experts to investigate the burden of filling in our question-
naires showed that at baseline as well as at follow-up 15 to 30
minutes were needed for a complete response. This was judged
to be acceptable and patients were informed of this time estima-
tion before providing informed consent to participate.
Challenges in conducting a study
Patient recruitment
Many studies fail to recruit enough patients which com-
promise statistical power. A review by Mc Donald showed
that only 31% of randomised controlled trials were able
to reach their goals concerning patient recruitment [12].
There are several ways to recruit patients: from medical
records, by advertisement or during consultation. The
usage of medical records increases effective recruitment
because it does not depend on patient presentation to
recruiters during the inclusion period. However, this
method can not be used when incident cases are required.
Sellors et al. found barriers such as the availability of elec-
tronic medical records, the experience of office staff and
GPs to produce patient sampling frames and ethical con-
siderations [13]. Another method is patient recruitment
via advertisements in (local) media or via flyers at the GP's
office. However, patients responding to such advertise-
ments may differ from patients not responding which
leads to selection bias and hampers external validity. The
conventional way to recruit patients is by the GP during
consultation (incident cases). This way of recruitment
approximates routine practice the most, which increases
external validity. However, it poses a huge burden on the
GP and is not always successful. There might simply be a
lack of eligible patients or trial procedures can be too
restrictive. According to Van Der Windt et al. the main rea-
sons for not referring eligible patients to the research cen-
tre by participating GPs were: busy surgery hours,
forgetfulness, or the conviction that a patient would ben-
efit more from a specific intervention[14]. De Wit et al.
found that successful patient recruitment in a dyspepsia
trial was determined more by the motivation of GPs by
the research group than by financial incentives, research
topic, or research experience[15]. Foy et al. investigated in
a meta-analysis the impact of interventions on patient
recruitment and concluded that organisational character-
istics (e. g. strong trial infrastructure) seemed to be impor-
tant [16]. Furthermore, many interventions on patient
recruitment were not evidence-based but based on the
experience of the investigator [16].
Additionally, successful patient recruitment depends on
the patients' motivation. Chang et al. found that the rea-
sons for patients to participate could be divided into six
general categories: 1) benefit to self; 2) benefit to others;
3) gratitude to the physician; 4) positive comments by the
trusted professional; 5) the appearance, personality, man-
ner and gender of the recruiter; 6) monetary compensa-
tion [17]. We agree with Chang that the most effective
recruitment involves a direct and personal approach [17].
Patients appeared to enjoy being noticed and sorted out
for something presented to them as important and spe-
cial. The patient information and the GP need to address
possible reasons and advantages for patients to partici-
pate.
The rationale behind our choices
Since we focused on patients with a new episode of complaints,
we chose to recruit incident cases during consultations by the
GP. To our experience successful patient recruitment depends
on: 1) Close monitoring of recruitment statistics and extra
measures to boost recruitment if necessary; 2) flexibility of the
research protocol: it must be possible to adapt the protocol when
GPs cannot use it in practice or when selection criteria are not
clear or too strict; 3) good and regular contact with the GP or
an assistant (preferably face-to-face or by telephone), which
enables to remind and motivate them and notice and resolve
difficulties. We visited the GPs after each new included patient
to collect the patient's blood sample and provide new materials.
The purpose of this visit was to reinforce the patient inclusion,
but not to discuss how the included patient was treated to avoid
an extra educational intervention. Furthermore, a monthly
newsletter was sent to the GPs to remind them and to keep them
posted. We tried to minimize the burden for the GPs and the
assistants (for instance by taking blood samples ourselves when
necessary) and answered questions promptly implying easy
accessibility. Despite these efforts to motivate and assist the
GPs, only 48% of the participating GPs recruited one or more
patients (Figure 4). We can only speculate on the reasons for
this disappointing number: maybe the inclusion and treatment
was expected to be too time-consuming or maybe these GPs sim-
ply forgot to invite eligible patients despite of several reminders.
Social desirability may have caused GPs to participate who were
less motivated to include patients. Although ultimately success-
ful, patient recruitment was very time consuming and needed
sufficient budget for recruitment personnel. The intended inclu-
sion period of two years had to be prolonged in October 2005
to include the desired number of patients. Only GPs who were
expected to include several patients before the end of 2005
("promising" GPs) were invited to continue patient recruit-
ment. This explains the sudden fall in participating GPs in Fig-
ure 4. Interestingly, this did not decrease the patient inclusion
in the last months, which suggests that it may be more efficient
to only include highly motivated and "promising" GPs. Exclu-
sion of reluctant GPs may hardly decrease inclusion rates but
does decrease the workload for the researchers.BMC Medical Research Methodology 2007, 7:16 http://www.biomedcentral.com/1471-2288/7/16
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GP recruitment
Patient recruitment in primary care based trials often
depends on the cooperation of GPs. Since the demand on
GPs to participate in research is growing and it is hard to
keep the balance between research participation and daily
practice, GPs must be very critical in their decision to par-
ticipate[15]. Factors known to influence the physician's
decision to participate include: 1) a personal interest in
the research topic; 2) the relevance of the research ques-
tion; 3) the personal connection with the researchers; 4)
the collective ownership of the project; 5) the support of
stakeholders or respected members of the professional
community; 6) the revenue of costs associated with
research participation; 7) the simplicity of protocols with
low interference with patient care; 8) the availability of
practice staff to assist the enrolment; 9) the timeliness of
patient recruitment; 10) the satisfaction with study partic-
ipation [18-20]. Van Der Windt et al. also mentioned that
(accredited) postgraduate training is a reason for GPs to
participate, and involvement in too many other studies is
a reason not to participate[14].
A strategy for approaching primary care settings as pro-
posed by Murphy et al. and Kocken et al. recommends
identification of stakeholders and regional opinion lead-
ers, using support letters by relevant professional organi-
sations and supplying adequate, but concise, information
[18,21]. It is important to consider and address the rea-
sons for GPs to participate during the recruitment.
The rationale behind our choices
For GP recruitment we wanted to invite as many GPs as possi-
ble within our geographical boundaries to gather a large heter-
ogeneous GP sample. We retrieved the addresses of all eligible
primary care settings from a registration at the three participat-
ing universities. The GPs received an invitation letter with
information about the research together with a recommenda-
tion letter from the Dutch College of General Practitioners and
the Dutch Institute for Healthcare Improvement. A reply form
was offered to respond by fax. In case of non-response the GP
was invited again by means of a telephone call. After an infor-
mal appointment at the GP's office, the GP decided whether or
not to participate. For practical reasons the GP recruitment was
spread out over the first period of patient inclusion. The results
of GP recruitment are given in Figure 4. To our experience,
however ultimately successful, the GP recruitment was very
time consuming because of the many phone calls and visits.
Although difficult, personal contact with the GP more positively
influenced participation than leaving a message with the assist-
ant. Spreading out the GP recruitment period gave us the
opportunity to adjust the information letters and to approach
more GPs to boost patient recruitment when the inclusion
lagged behind. Our method of GP recruitment probably has
resulted in a heterogeneous and representative relatively large
GP sample, which is likely to have a positive influence on the
generalisability of the results.
Protocol deviations
Protocol deviation or protocol non-adherence by
patients, GPs or researchers is common. Examples of pro-
tocol deviations are: drop-out, inclusion of ineligible
patients, not receiving the allocated treatment, unplanned
interruption or abortion of treatment; and not taking the
trial medication as prescribed. Drop-outs are patients who
stop their trial medication but remain available for fol-
low-up [22]. Patients can also be "lost to follow-up",
when they are no longer accessible to the investigators
[22]. Eligibility errors are relatively common [22]. Objec-
tive eligibility criteria are less prone to error than subjec-
tive ones. If eligibility is checked before randomisation,
the consequences of such errors will be minimal. How-
ever, in pragmatic trials commonly the eligibility is
checked e.g. with blood measurements or patient self-
reports, which are often only available after randomisa-
tion.
Bias can be introduced when protocol deviation affects
both treatment groups differently [22]. Researchers there-
fore investigate whether the protocol deviation is caused
by systematic or random errors, and whether it causes dif-
ferences between both treatment groups. When protocol
deviation is associated with one treatment arm (e.g. if the
experimental treatment has more side-effects), it is impor-
tant to take this into account because protocol deviations
will also happen in every day practice. In a per-protocol
analysis all patients with a protocol deviation will be
excluded, which contrasts with the purpose of conducting
a pragmatic trial [23]. Exclusion of patients can result in
bias when the patients that stay included are no longer
representative for the study population. Therefore, a per-
protocol analysis is less suitable than an intention-to-treat
analysis for pragmatic trials. Some pragmatic trials per-
form a per-protocol analysis additionally to an intention-
to-treat analysis, but difficulties arise when both analysis
produce different results. Whereas the results of a per-pro-
tocol analysis may provide additional insights in why a
treatment has (or lacks) effect in every day practice, in
pragmatic trials the intention-to-treat analysis is the way
to determine the overall effect.
Protocol deviations can partly be prevented by writing
simple and clear protocols, providing proper patient
information, and by closely monitoring GPs and patients
during a pilot study and adjusting the protocol if required.
The rationale behind our choices
To reflect every day practice as much as possible we chose to
write a flexible treatment protocol, in which for instance the GP
was free to decide when patients could return for consultationBMC Medical Research Methodology 2007, 7:16 http://www.biomedcentral.com/1471-2288/7/16
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(after 4 weeks was recommended) or how the consultation was
done, by phone or personal. This has probably minimized our
number of protocol deviations. We can only present some pre-
liminary data at this moment, since not all analyses have yet
been finished. No non-eligible patients were included. Eleven
patients gave an informed consent but changed their mind
shortly after and they did not start using our trial medication.
One patient did not use medication step 1 for unknown rea-
sons, but started medication step 2 approximately two weeks
after baseline. Table 5 shows the questionnaire response rates
and suggests that number of patients "lost to follow" up was
limited. For the intention-to-treat analysis, preliminary results
indicate that for 98% of the patients the primary outcome at 6
months is present. We are able to achieve such a high response
rate by contacting all non-responders or drop-outs by phone or
via the GP (except for patients indicating not to be willing/able
to participate anymore) and asking them to answer the ques-
tion: has symptom relief been adequate since the start of the
treatment? Most patients are willing to answer this single ques-
tion.
Some patients do not return the initial 6 month questionnaire,
because they think that when their complaints are resolved they
do not need to return questionnaires. To prevent this bias we
send reminders pointing out the importance of always returning
the questionnaire and contact non-responders by phone or via
their GPs. The preliminary response rates for all questionnaires
are given in Table 5. The response rates slowly decrease in time
as can be expected. The length of the baseline questionnaire
(T0) and the high number of questionnaires during the first
month caused several patients to stop their participation.
Although tested in a pilot study and explained in the patient
information, this could not be completely prevented. Maybe in
the near future easier ways to monitor complaints and retrieve
important data (e.g. via the internet) will become accessible
and can facilitate patient cooperation and prevent drop-out.
The consequences of our choices for the usefulness and 
relevance of the DIAMOND results
The results of this study are useful/relevant for policy mak-
ers, patients, GPs and researchers because a large popula-
tion of well defined patients, which is generalisable to the
Dutch population of patients with a new episode of dys-
peptic symptoms. The study has a high internal validity
because of the random treatment allocation, and the con-
cealment of treatment allocation/blinding, which
increases the value of the results for policy makers. How-
ever, the external validity is decreased by the use of step-
down treatment instead of PPI-treatment (which is more
common in every day practice) and by the blinding. Con-
sequently, it is difficult to say what the effect of both treat-
ment strategies will be if performed in every day practice.
In order to adapt the study protocol to routine daily prac-
tice, a multistep protocol was designed. Although this
resembles everyday practice it makes analysis more diffi-
cult, because not all patients are in the same treatment
step at a certain point in time, and because the period of
time between finishing the trial medication and registra-
tion of the primary outcome may vary from patient to
patient. In case this period is long, the primary outcome
may be influenced by follow-up treatment chosen by the
GP. This may decrease any differences between the treat-
ment strategies, but on the other hand the primary out-
come does provide essential information about the
effectiveness of actual primary care treatment for dyspep-
sia. Furthermore, the differences between the two treat-
ment strategies can be analyzed in more detail by
analyzing the secondary endpoints (at 4 weeks, 12 weeks,
etc...). Therefore, the trial design as presented will provide
important insights in various strategies for treatment of
dyspepsia in primary care.
Summary
Pragmatic trials must ensure a high generalisability with-
out compromising internal validity, which is very chal-
lenging [24]. Therefore, a critical appraisal of the planned
design and method to conduct the trial before actually
starting to collect data is essential. When several publica-
tions on patient recruitment or other pitfalls in designing/
conducting a pragmatic trial are consulted, one may
increase the likelihood of conducting a successful trial.
Furthermore, it is very important to set priorities before-
hand where on the 'spectrum from explanatory to prag-
matic' you want your trial to be: do you want to know the
"unbiased" effect of the treatment (as in explanatory tri-
Table 5: Preliminary results*: the patient questionnaire response rates
N = 664* Baseline 2 weeks After step 1 After step 2# After step 3# 6 months 1 year
Sent out 664* 613* 643* 595* 587* 659* 566*
Returned 629 543 525 474 454 646 373
Response rate 95% 86% 82% 80% 77% 98% 66%^
* Not all follow-up questionnaires were sent out, for instance when patients started step 2 within 2 weeks, or patients reported they no longer 
whish to receive questionnaires.
# if medication of this step was not started, questionnaires were sent out at 2 resp. 3 months.
^In case of non-response a reminder is sent out after all questionnaires except after 1-year, since this is an additional measurement to the original 
research protocol. This explains the low response rate.BMC Medical Research Methodology 2007, 7:16 http://www.biomedcentral.com/1471-2288/7/16
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als) or are you more interested in the effects in daily pri-
mary care (as in pragmatic trials)? For instance, we chose
to blind treatment allocation because otherwise preju-
dices of GPs, patients and researchers might have biased
the results, although blinding contrasts with the purpose
to reflect every day practice in pragmatic trials. On the
other hand, we chose to use flexible treatment protocol to
reflect every practice, what again might contrast with
using standardized treatment in explanatory trials.
This paper shows that while we did not compare the two
most frequently used treatment strategies in the DIA-
MOND-study, we were still able to collect highly valid
data because of the blinded randomised treatment, the
randomly selected heterogeneous patient sample and the
research protocol that closely fits to normal practice.
Although it is very difficult to recruit as many GPs and
patients as needed, success can be determined by careful
consideration of how the GPs and patients will be opti-
mally recruited and what their reasons to participate or to
refuse participation will be. Our experiences with the DIA-
MOND-study give an indication of what success rates
regarding GP and patient recruitment and questionnaire
response can be expected in similar studies.
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